Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
2010
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
2006 StandoutScience
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype
2016 StandoutNobel
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
2009
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Gut microbiota-derived propionate reduces cancer cell proliferation in the liver
2012
Trastuzumab therapy in Australia: Which patients with HER2+ metastatic breast cancer are assessed for cardiac function?
2013
Triple-Negative Breast Cancer: An Unmet Medical Need
2011
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Triple-Negative Breast Cancer
2010 Standout
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
2012
Cardiac side-effects of cancer chemotherapy
2010
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
2009 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Cancer Treatment–Related Cardiotoxicity: Current State of Knowledge and Future Research Priorities
2014
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
2012
Polymer-drug conjugates: Recent development in clinical oncology
2008
Imaging in the era of molecular oncology
2008 StandoutNature
Prodrug Strategies in Anticancer Chemotherapy
2007
Cancer drug resistance: an evolving paradigm
2013 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial
2002 Standout
Chemotherapy-Induced Cardiotoxicity: Detection, Prevention, and Management
2014
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
2010
The REDCap consortium: Building an international community of software platform partners
2019 Standout
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
2011
Assessing responses to cancer therapy using molecular imaging
2006
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
2011
Phase II Trial of Combination of Pegylated Liposomal Doxorubicin, Cisplatin, and Infusional 5-Fluorouracil (CCF) Plus Trastuzumab as Preoperative Treatment for Locally Advanced and Inflammatory Breast Cancer
2010
Design considerations for tumour-targeted nanoparticles
2009 StandoutNobel
Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
2012
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
2012
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy
2009
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
2010
Chemotherapy for Malignant Pleural Mesothelioma
2003
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Application of Nanotechnology in Cancer Therapy and Imaging
2008
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study
2012
Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis
2011 Standout
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy
2014
Microtubules as a target for anticancer drugs
2004 Standout
Small-molecule delivery by nanoparticles for anticancer therapy
2010
Cardiovascular effects of systemic cancer treatment
2010
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
2009
Clonal evolution in cancer
2012 StandoutNature
A feasibility study to evaluate breast cancer patients’ knowledge of their diagnosis and treatment
2012
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Clinical imaging of cancer metastasis
2000
Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer
2005
Microbiota-Generated Metabolites Promote Metabolic Benefits via Gut-Brain Neural Circuits
2014 Standout
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer
2011
Cancer Chemotherapy and Cardiac Arrhythmias: A Review
2015
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group
2015
Advances in Malignant Mesothelioma
2005 Standout
Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy
2007
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper
2010
Cancer drugs and the heart: importance and management
2012
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors
2011
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II Study
1999
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway
2017 StandoutNobel
Drug-Induced Oxidative Stress and Toxicity
2012
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Breast Cancer Treatment
2019 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial
2005
Nanoparticles in Photodynamic Therapy
2015 Standout
Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein
2003
Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation
2010
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
2016
Nanoparticle PEGylation for Imaging and Therapy
2011 Standout
Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology
2005
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform
2011 Standout
Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
2011 Standout
Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions
2013
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
2002 StandoutScience
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
2010
Light-Controlled Radical Polymerization: Mechanisms, Methods, and Applications
2016 Standout
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Metal–Organic Frameworks in Biomedicine
2011 Standout
pH-Operated Nanopistons on the Surfaces of Mesoporous Silica Nanoparticles
2010 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
The Structure of Anthracycline Derivatives Determines Their Subcellular Localization and Cytotoxic Activity
2013
Cardiac toxicity in cancer survivors
2013
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Localized Ewing Tumor of Bone: Final Results of the Cooperative Ewing’s Sarcoma Study CESS 86
2001
Clinical Translation of Nanomedicine
2015
Works of Mark Verrill being referenced
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
2010
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
2009
Ewing's sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children?
1997
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
2010
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2)
2005
Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study
2000
Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial
2004
Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma
2000
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk
2009
Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma
2002
Effect of tandem high-dose chemotherapy (HDC) on long-term complete remissions (LTCR) in metastatic breast cancer (MBC), compared to conventional dose (CDC) in patients (pts) who were not selected on the basis of response to prior C: Mature results of the IBDIS-I
2004
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
2008
A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules
2005
Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized31P measurements of response to treatment
1998
75 Good symptom relief with palliative MVP (mitomycin c, vinblastine, cisplatin) chemotherapy in malignant mesothelioma
1997